Ionis Pharmaceuticals (IONS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $42.94, -2.67% vs the prior close of $44.12.
- Volume 1.67M shares, 0.5x its 50-day average (light).
- New SEC filings: 144 (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
IONS dips 2.7% to $42.94. Closed at $42.94, -2.67% vs the prior close of $44.12. Day range $42.79–$44.65, opened at $44.53.
IONS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — IONS dips 2.7% to $42.94
- Closed at $42.94, -2.67% vs the prior close of $44.12. Day range $42.79–$44.65, opened at $44.53.
- Volume was 1.67M shares, 0.5x its 50-day average of 3.30M — lighter than usual.
- Price is -17.0% vs its 50-day average ($51.73) and -37.4% vs its 200-day average ($68.60).
- 52-week range $42.08–$86.74; today's close sits at 2% of that range, 50.5% below the 52-week high.
Oct 15, 2026 — IONS jumps 3.3% to $44.12
- Closed at $44.12, +3.33% vs the prior close of $42.70. Day range $43.42–$44.71, opened at $43.58.
- Volume was 2.48M shares, 0.8x its 50-day average of 3.29M.
- Price is -15.1% vs its 50-day average ($51.96) and -35.9% vs its 200-day average ($68.78).
- 52-week range $42.08–$86.74; today's close sits at 5% of that range, 49.1% below the 52-week high.
Oct 14, 2026 — IONS rises 0.8% to $42.70
- Closed at $42.70, +0.76% vs the prior close of $42.38. Day range $42.08–$43.47, opened at $42.22.
- Volume was 2.03M shares, 0.6x its 50-day average of 3.31M.
- Price is -18.1% vs its 50-day average ($52.16) and -38.1% vs its 200-day average ($68.96).
- 52-week range $42.08–$86.74; today's close sits at 1% of that range, 50.8% below the 52-week high.
Oct 13, 2026 — IONS dips 3.0% to $42.38, a 52-week low
- Closed at $42.38, -2.95% vs the prior close of $43.67. Day range $42.36–$43.58, opened at $43.55.
- Volume was 2.98M shares, 0.9x its 50-day average of 3.31M.
- Price is -19.1% vs its 50-day average ($52.40) and -38.7% vs its 200-day average ($69.14).
- 52-week range $42.36–$86.74; today's close sits at 0% of that range, 51.1% below the 52-week high.
Oct 12, 2026 — IONS slides 3.6% to $43.67
- Closed at $43.67, -3.56% vs the prior close of $45.28. Day range $43.62–$45.46, opened at $45.37.
- Volume was 1.95M shares, 0.6x its 50-day average of 3.32M — lighter than usual.
- Price is -17.1% vs its 50-day average ($52.65) and -37.0% vs its 200-day average ($69.34).
- 52-week range $42.63–$86.74; today's close sits at 2% of that range, 49.7% below the 52-week high.
Oct 9, 2026 — IONS jumps 4.6% to $45.28
- Closed at $45.28, +4.57% vs the prior close of $43.30. Day range $43.12–$45.72, opened at $43.21.
- Volume was 4.86M shares, 1.5x its 50-day average of 3.28M.
- Price is -14.3% vs its 50-day average ($52.81) and -34.9% vs its 200-day average ($69.52).
- 52-week range $42.63–$86.74; today's close sits at 6% of that range, 47.8% below the 52-week high.
Oct 8, 2026 — IONS dips 1.9% to $43.30, a 52-week low
- Closed at $43.30, -1.95% vs the prior close of $44.16. Day range $42.79–$44.19, opened at $43.76.
- Volume was 3.35M shares, 1.0x its 50-day average of 3.28M.
- Price is -18.3% vs its 50-day average ($52.97) and -37.9% vs its 200-day average ($69.70).
- 52-week range $42.63–$86.74; today's close sits at 2% of that range, 50.1% below the 52-week high.
Oct 7, 2026 — IONS rises 0.4% to $44.16
- Closed at $44.16, +0.36% vs the prior close of $44.00. Day range $43.53–$44.26, opened at $43.75.
- Volume was 2.94M shares, 0.9x its 50-day average of 3.28M.
- Price is -17.0% vs its 50-day average ($53.18) and -36.8% vs its 200-day average ($69.88).
- 52-week range $42.63–$86.74; today's close sits at 3% of that range, 49.1% below the 52-week high.
Oct 6, 2026 — IONS rises 1.1% to $44.00
- Closed at $44.00, +1.15% vs the prior close of $43.50. Day range $43.17–$44.67, opened at $44.19.
- Volume was 2.19M shares, 0.7x its 50-day average of 3.28M.
- Price is -17.6% vs its 50-day average ($53.41) and -37.2% vs its 200-day average ($70.05).
- 52-week range $42.63–$86.74; today's close sits at 3% of that range, 49.3% below the 52-week high.
Oct 5, 2026 — IONS ends flat (-0.1%) to $43.50, a 52-week low, 4 down days in a row
- Closed at $43.50, -0.09% vs the prior close of $43.54. Day range $42.63–$43.96, opened at $43.75.
- Volume was 2.87M shares, 0.9x its 50-day average of 3.29M.
- Price is -18.9% vs its 50-day average ($53.65) and -38.0% vs its 200-day average ($70.21).
- 52-week range $42.63–$86.74; today's close sits at 2% of that range, 49.9% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — IONS dips 1.0% to $43.54, a 52-week low, 3 down days in a row
- Closed at $43.54, -1.05% vs the prior close of $44.00. Day range $43.24–$44.17, opened at $44.17.
- Volume was 2.31M shares, 0.7x its 50-day average of 3.32M.
- Price is -19.2% vs its 50-day average ($53.91) and -38.1% vs its 200-day average ($70.39).
- 52-week range $43.01–$86.74; today's close sits at 1% of that range, 49.8% below the 52-week high.
- That makes 3 straight losses.
IONS latest news & SEC filings
Every SEC filing by or about IONS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hayden Michael R bought 5,000 shares at $51.60 (≈$258.00K) on Jul 31, 2026
- Hayden Michael R bought 5,000 shares at $51.60 (≈$258.00K) on Jul 31, 2026
- Hayden Michael R bought 5,000 shares at $51.60 (≈$258.00K) on Jul 31, 2026
- Hayden Michael R bought 5,000 shares at $51.60 (≈$258.00K) on Jul 31, 2026
- Hayden Michael R bought 15,000 shares at $53.38 (≈$800.70K) on Jul 30, 2026
- Hayden Michael R bought 15,000 shares at $53.38 (≈$800.70K) on Jul 30, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 31, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 29, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $267.95M (prior year $452.05M) (-40.7% vs Jun 30, 2025)
- Net income: -$114.65M (prior year $123.55M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.69 (prior year $0.70) (loss widened vs Jun 30, 2025)
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade IONS
- Last results release: Jul 29, 2026 (8-K Item 2.02). Previous ones: Apr 29, 2026, Feb 25, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 28, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.92% (largest 4.6%).
- Liquidity: about 3.34M shares (≈$143.57M) trade per day on average.
- 52-week position: $42.94 vs a range of $42.08–$86.74 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 17 sales; latest: Michael R Hayden bought 5,000 shares on Jul 31, 2026.
- Latest filings: 8-K Sep 23, 2026; 8-K Sep 4, 2026; 8-K Sep 4, 2026.
- Share count: 166.18M shares outstanding (Jul 23, 2026), +4.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
IONS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 44.53 | 44.65 | 42.79 | 42.94 | 1.67M |
| Oct 15, 2026 | 43.58 | 44.71 | 43.42 | 44.12 | 2.48M |
| Oct 14, 2026 | 42.22 | 43.47 | 42.08 | 42.70 | 2.03M |
| Oct 13, 2026 | 43.55 | 43.58 | 42.36 | 42.38 | 2.98M |
| Oct 12, 2026 | 45.37 | 45.46 | 43.62 | 43.67 | 1.95M |
| Oct 9, 2026 | 43.21 | 45.72 | 43.12 | 45.28 | 4.86M |
| Oct 8, 2026 | 43.76 | 44.19 | 42.79 | 43.30 | 3.35M |
| Oct 7, 2026 | 43.75 | 44.26 | 43.53 | 44.16 | 2.94M |
| Oct 6, 2026 | 44.19 | 44.67 | 43.17 | 44.00 | 2.19M |
| Oct 5, 2026 | 43.75 | 43.96 | 42.63 | 43.50 | 2.87M |
| Oct 2, 2026 | 44.17 | 44.17 | 43.24 | 43.54 | 2.31M |
| Oct 1, 2026 | 44.63 | 45.95 | 43.96 | 44.00 | 2.03M |
| Sep 30, 2026 | 46.07 | 46.25 | 44.60 | 44.65 | 2.63M |
| Sep 29, 2026 | 45.53 | 46.46 | 45.39 | 45.89 | 3.89M |
| Sep 28, 2026 | 44.56 | 46.95 | 44.06 | 45.57 | 3.74M |
| Sep 25, 2026 | 44.25 | 45.28 | 43.62 | 44.50 | 6.20M |
| Sep 24, 2026 | 43.77 | 44.60 | 43.25 | 43.81 | 6.45M |
| Sep 23, 2026 | 46.23 | 46.41 | 43.01 | 43.93 | 3.54M |
| Sep 22, 2026 | 44.96 | 46.13 | 44.44 | 45.75 | 4.23M |
| Sep 21, 2026 | 44.95 | 45.25 | 44.20 | 44.90 | 4.52M |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals (IONS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CARLSBAD, CA. State of incorporation: CA. Fiscal year ends December 31. SEC CIK 874015.
IONS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Spencer R Berthelsen | Director | Jul 17, 2026 |
| Allene M. Diaz | Director | Jul 9, 2026 |
| Ludwig Hantson | Director | Jul 17, 2026 |
| Joan E Herman | Director | Jul 17, 2026 |
| Michael R Hayden | Director | Jul 31, 2026 |
| Joseph Iii Klein | Director | Jul 6, 2026 |
| Joseph Loscalzo | Director | Jul 6, 2026 |
| Brett P Monia | Chief Executive Officer | Sep 2, 2026 |
| B Lynne Parshall | Director | Apr 17, 2026 |
| Peter N Reikes | Director | Jul 17, 2026 |
| Joseph H Wender | Director | Dec 3, 2025 |
| Michael J. Yang | Director | Jul 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| C Frank Bennett | EVP, Chief Scientific Officer | Sep 2, 2026 |
| Joseph Baroldi | EVP, Chief Business Officer | Jun 30, 2026 |
| Brian Birchler | EVP, Corp and Development Ops | Sep 2, 2026 |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | Apr 2, 2026 |
| Richard S Geary | EVP, Chief Development Officer | Nov 7, 2025 |
| Elizabeth L Hougen | EVP, Finance & CFO | Mar 18, 2026 |
| Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | Apr 17, 2026 |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | Jul 9, 2026 |
| Brett P Monia | Chief Executive Officer | Sep 2, 2026 |
| Patrick R. O'Neil | EVP CLO & General Counsel | Sep 2, 2026 |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Jun 30, 2026 |
| Eric Swayze | EVP Research | Jun 26, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 31, 2026 | Michael R Hayden | Buy | 5,000 | $51.60 |
| Jul 31, 2026 | Michael R Hayden | Buy | 5,000 | $51.60 |
| Jul 31, 2026 | Michael R Hayden | Buy | 5,000 | $51.60 |
| Jul 31, 2026 | Michael R Hayden | Buy | 5,000 | $51.60 |
| Jul 30, 2026 | Michael R Hayden | Buy | 15,000 | $53.38 |
| Jul 30, 2026 | Michael R Hayden | Buy | 15,000 | $53.38 |
| Jul 30, 2026 | Michael R Hayden | Buy | 15,000 | $53.38 |
| Jul 30, 2026 | Michael R Hayden | Buy | 15,000 | $53.38 |
| Jul 7, 2026 | Holly B. Kordasiewicz | Sale | 362 | $84.30 |
| Jul 7, 2026 | Holly B. Kordasiewicz | Sale | 362 | $84.30 |
| Jul 7, 2026 | Holly B. Kordasiewicz | Sale | 362 | $84.30 |
| Jul 7, 2026 | Holly B. Kordasiewicz | Sale | 362 | $84.30 |
| Jul 7, 2026 | C Frank Bennett | Sale | 15,000 | $85.46 |
| Jul 7, 2026 | C Frank Bennett | Sale | 5,536 | $83.58 |
| Jul 7, 2026 | C Frank Bennett | Sale | 15,000 | $85.46 |
IONS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $943.71M | $-381.39M | -2.38 | $-268.58M |
| Dec 31, 2024 | $705.14M | $-453.90M | -3.04 | $-500.95M |
| Dec 31, 2023 | $787.65M | $-366.29M | -2.56 | $-307.51M |
| Dec 31, 2022 | $587.37M | $-269.72M | -1.90 | $-274.37M |
| Dec 31, 2021 | $810.46M | $-28.60M | -0.20 | $30.80M |
Latest balance sheet: total assets $2.99B, total liabilities $2.55B, cash $350.06M (as of Jun 30, 2026).
IONS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 29, 2026 | 8-K Item 2.02 (results) | $54.04 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $74.83 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $80.93 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $81.66 |
| Oct 29, 2025 | 8-K Item 2.02 (results) | $71.88 |
| Jul 30, 2025 | 8-K Item 2.02 (results) | $43.37 |
| Apr 30, 2025 | 8-K Item 2.02 (results) | $30.71 |
| Feb 19, 2025 | 8-K Item 2.02 (results) | $31.81 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $39.04 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 21, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on IONS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.